FDA cited Half Hill Farm's mushroom extracts as unapproved new drugs over website disease-treatment claims.
What happened
FDA inspected the facility at 110 W. High St., Woodbury, TN, from 05/28/25 to 05/30/25 and reviewed labeling collected during the inspection and the website www.halfhillfarm.com in February 2026. FDA found that the website cited publications linking Turkey Tail, Chaga, and Red Reishi mushroom extracts to cancer, herpes, and other diseases, which FDA treated as evidence the products are intended as drugs. FDA also found the products misbranded because they lack adequate directions for use.
What FDA found
FDA said citing publications can be a disease claim when the citation refers to a disease use and implies treatment or prevention.
21 CFR 101.93(g)(2)(iv)(C)FDA said website citations to cancer and other disease research show the mushroom extracts are intended to treat disease, making them new drugs without FDA approval.
sections 201(g)(1)(B), 301(d), and 505(a) of the Act [21 U.S.C. 321(g)(1)(B), 331(d), 355(a)]FDA said the products are not generally recognized as safe and effective for the cited disease uses, so they meet the definition of new drugs.
section 201(p) of the Act [21 U.S.C. 321(p)]FDA said the products are misbranded because they do not bear adequate directions for a layperson to use them safely for their intended disease uses.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5FDA said introducing or delivering these misbranded drugs into interstate commerce violates the Act.
section 301(a) of the Act [21 U.S.C. 331(a)]FDA said the company's June 13, 2025 response did not include documentation that the label changes it described had been made.
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt of the letter of the specific steps taken to address the violations, including an explanation and documentation to prevent recurrence. If corrective actions cannot be completed in that time, the company must state the reason and the time within which it will do so.
Who should pay attention
- dietary supplement brands that cite research on product websites
- mushroom extract sellers and distributors
- retailers that carry supplements with disease-treatment claims
This is a summary. Read the original letter on fda.gov.